No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 12 of the 39 quarters in the window, leaving 27 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 50.3x · 10Y median 22.4x · 95th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:37:39.545Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Nutriband Inc. (NTRB) stock was $6.70 as of Oct 6, 2026, 3:34 PM EDT, down 10.37% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -4.7% · 3-year avg +47.6%/yr · 5-year avg +6.7%/yr
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches.
Biotechnology · Orlando, FL
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-01-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Dec 7, 2026
62 days away
EPS Estimate
N/A
Revenue Est.
$465000.00
Last Quarter Results
EPS
$-0.04
vs Estimate
$-1.89
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NTRB | $81.38M | $6.70 | -10.37% | -4.74% | +6.67% | N/A | N/A |
| 2PMN | $81.70M | $9.11 | -2.77% | -24.64% | -47.05% | -22.51% | vs NTRB |
| 3HUMA | $80.89M | $0.48 | -3.70% | -76.03% | -45.73% | N/A | vs NTRB |
| 4LNSR | $82.04M | $6.68 | +0.15% | -45.13% | -3.18% | N/A | vs NTRB |
| 5TELO | $82.53M | $1.20 | -0.83% | -13.51% | N/A | N/A | vs NTRB |
| 6ACRV | $80.04M | $1.87 | -5.56% | +3.65% | N/A | N/A | vs NTRB |
4.26
$437514.00
vs Estimate
$437514.00
Consensus Rating
Based on 1 analyst
Average Price Target
$15.00
+124.0% upside
Low
$15.00
Current
$6.70
High
$15.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Oct 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jan 2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Quarter ending Apr 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Quarter ending Jul 2027 | $-0.14 | $-0.14 | $-0.14 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $1.57 | $1.57 | $1.57 | 1 |
| FY 2028 | $3.66 | $3.66 | $3.66 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Oct 2026 | $465000.00 | $465000.00 | $465000.00 | 1 |
| Quarter ending Jan 2027 | $433500.00 | $433500.00 | $433500.00 | 1 |
| Quarter ending Apr 2027 | $213700.00 | $213700.00 | $213700.00 | 1 |
| Quarter ending Jul 2027 | $332234.00 | $332234.00 | $332234.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Jan 31, 2027, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $95.41M | $95.41M | $95.41M | 1 |
| FY 2028 | $180.41M | $180.41M | $180.41M | 1 |
